IP Verse

Methods And Compositions For Selectively Eliminating Cells Of Interest - EP3230460

The patent EP3230460 was granted to ZHU on Nov 29, 2023. The application was originally filed on Dec 14, 2015 under application number EP15868327A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3230460

ZHU
Application Number
EP15868327A
Filing Date
Dec 14, 2015
Status
Patent Maintained As Amended
Oct 27, 2023
Grant Date
Nov 29, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CAMULONJul 6, 2021CARRIDGEADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2014172470
INTERNATIONAL-SEARCH-REPORTUS2013326645
INTERNATIONAL-SEARCH-REPORTUS6537805
INTERNATIONAL-SEARCH-REPORTWO2014113493
OPPOSITIONUS2013326645
OPPOSITIONUS2015071946
OPPOSITIONWO2010117464
OPPOSITIONWO2013158309
OPPOSITIONWO2014059173
OPPOSITIONWO2014165707
OPPOSITIONWO2014172470
OPPOSITIONWO2016011428
SEARCHUS2011130444
SEARCHWO2008136656

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- WIRTH, THOMAS et al., "History of gene therapy", Gene, (20130423), vol. 525, no. 2, doi:doi:10.1016/j.gene.2013.03.137, pages 162 - 169, XP 028576972 [A] 2-16, 20-25 * See the whole document. *-
INTERNATIONAL-SEARCH-REPORT- ZHONG, BONAN et al., "Safeguarding nonhuman primate iPS cells with suicide genes", Molecular Therapy, (20110517), vol. 19, no. 9, pages 1667 - 1675, XP055454510 [X] 20-21, 24-25 * See abstract; page 1667, right column, paragraph 1; page 1672, right column, paragraph 3. * [Y] 2-16, 22-23
OPPOSITION- AMER, "Gene therapy for cancer: present status and future perspective", Molecular and Cellular Therapies, (20130000), vol. 2, pages 1 - 19-
OPPOSITION- CONG et al., "multiplex Genome engineering using CRISPR/Cas Systems", Science, (20130000), vol. 339, doi:10.1126/science.1231143, pages 819 - 823-
OPPOSITION- Cooper & Alder (2006) Cell 124. 815-822, (24.02.2006)-
OPPOSITION- Extracts from a sequence search for orthologs obtained from http//www.informatics.jax.org-
OPPOSITION- GAJ et al., "ZFN, TALEN and CRISPR/Cas-based methods for genome engineering", Trends Biotechnol, (20130000), vol. 31, no. 7, pages 397 - 405-
OPPOSITION- Gene Trees from comparative genomic searches from http://mart.ensembl.org/indey/html-
OPPOSITION- LI et al., "Safeguarding clinical translation of pluripotent stem cells with suicide genes", Organogenesis, (20130000), vol. 9, no. 1, doi:10.4161/org.24317, pages 34 - 39-
OPPOSITION- Luo et al. Nature Scientific Reports (2019) 9:1074-
OPPOSITION- Rosner Karli, "DNase1: a new personalized therapy for cancer?", Expert Rev. Anticancer Ther., (20110101), vol. 11, no. 7, pages 981 - 984-
OPPOSITION- Rosner Karli, "DNase1: a new personalized therapy for cancer?", Expert Rev. Anticancer Ther., (20110101), vol. 11, no. 7, pages 981 - 984, XP055825457-
OPPOSITION- Wikipedia extract (https.<7en.wikipedia org/wiki/Ex vivo)-
OPPOSITION- ZHONG et al., Safeguarding Nonhuman Primate iPS Cells With Suicide Genes Molecular Therapy, (20110000), vol. 19, no. 9, pages 1667 - 1675-
OPPOSITION- GAJ et al., "ZFN, TALEN and CRISPR/Cas-based methods for genome engineering", Trends Biotechnol, (20130000), vol. 31, no. 7, pages 397 - 405, XP055418607
OPPOSITION- ZHONG et al., Safeguarding Nonhuman Primate iPS Cells With Suicide Genes Molecular Therapy, (20110000), vol. 19, no. 9, pages 1667 - 1675, XP055454510
OPPOSITION- CONG et al., "multiplex Genome engineering using CRISPR/Cas Systems", Science, (20130000), vol. 339, doi:10.1126/science.1231143, pages 819 - 823, XP055458249
OPPOSITION- AMER, "Gene therapy for cancer: present status and future perspective", Molecular and Cellular Therapies, (20130000), vol. 2, pages 1 - 19, XP021198259
OPPOSITION- LI et al., "Safeguarding clinical translation of pluripotent stem cells with suicide genes", Organogenesis, (20130000), vol. 9, no. 1, doi:10.4161/org.24317, pages 34 - 39, XP055461402
SEARCH- L. CONG ET AL, "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, US, (20130103), vol. 339, no. 6121, doi:10.1126/science.1231143, ISSN 0036-8075, pages 819 - 823, XP055469277 [X] 10 * figure 1 * [Y] 1-9,11-15
SEARCH- MAGID H AMER, "Gene therapy for cancer: present status and future perspective", MOLECULAR AND CELLULAR THERAPIES, BIOMED CENTRAL LTD, LONDON, UK, (20140910), vol. 2, no. 1, doi:10.1186/2052-8426-2-27, ISSN 2052-8426, page 27, XP021198259 [A] 1-15 * page 6, column 1, paragraph 1 * * page 6, column 2, paragraph l * * page 8, column 1, paragraphs 2,3 *
SEARCH- WEIQIANG LI ET AL, "Safeguarding clinical translation of pluripotent stem cells with suicide genes", ORGANOGENESIS, US, (20130101), vol. 9, no. 1, doi:10.4161/org.24317, ISSN 1547-6278, pages 34 - 39, XP055461402 [Y] 1-9,11-15 * page 35, column 1, paragraph 2 * * page 36, column 1, paragraph 3 * * page 36, column 2, paragraph 3 - page 37, column 1, paragraph 1; table 2 * * page 38, column 1, paragraph 2 - page 38, column 2, paragraph 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents